EDOXABAN VERSUS WARFARIN IN 841 PATIENTS WITH ATRIAL FIBRILLATION AND PERIPHERAL ARTERIAL DISEASE: INSIGHTS FROM THE ENGAGE AF-TIMI 48 TRIAL

Peripheral arterial disease (PAD) is associated with ischemic and bleeding risk. The balance of efficacy and safety of various antithrombotics in pts with atrial fibrillation (AF) and PAD is unclear. We compared edoxaban and warfarin in pts with AF and PAD. ENGAGE AF-TIMI 48 randomized 21,105 pts